The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells

[1]  F. Schmitt,et al.  Microenvironment in breast tumorigenesis: Friend or foe? , 2019, Histology and histopathology.

[2]  A. Popel,et al.  Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis , 2018, Breast cancer research : BCR.

[3]  Junjeong Choi,et al.  Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells , 2018, Scientific Reports.

[4]  Wei Li,et al.  Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer , 2018, Oncology letters.

[5]  John H. White,et al.  Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  W. ElShamy,et al.  Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment , 2017, Oncotarget.

[7]  Woo-Jin Song,et al.  Immunomodulatory effects of soluble factors secreted by feline adipose tissue-derived mesenchymal stem cells. , 2017, Veterinary immunology and immunopathology.

[8]  A. Ramirez,et al.  An anti-inflammatory dietary intervention to reduce breast cancer recurrence risk: Study design and baseline data. , 2017, Contemporary clinical trials.

[9]  G. Di,et al.  Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  W. ElShamy,et al.  The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion , 2017, BMC Cancer.

[11]  L. Ricci-Vitiani,et al.  Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts , 2017, Stem Cell Research & Therapy.

[12]  E. Yoon,et al.  Mesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth. , 2017, Cell reports.

[13]  W. ElShamy,et al.  BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions , 2016, Oncotarget.

[14]  Zong-fang Li,et al.  Mesenchymal stem cells inhibited development of lung cancer induced by chemical carcinogens in a rat model. , 2017, American journal of translational research.

[15]  W. Woodward,et al.  Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models , 2016, Oncotarget.

[16]  W. ElShamy,et al.  Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors? , 2016, Stem cells international.

[17]  S. Szala,et al.  Human Cardiac Mesenchymal Stromal Cells with CD105+CD34- Phenotype Enhance the Function of Post-Infarction Heart in Mice , 2016, PloS one.

[18]  U. Jeschke,et al.  Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. , 2016, Anticancer research.

[19]  K. Kang,et al.  PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact , 2016, Scientific Reports.

[20]  H. Rosen,et al.  Essential Opposite Roles of ERK and Akt Signaling in Cardiac Steroid-Induced Increase in Heart Contractility , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[21]  F. Emmert-Streib,et al.  A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer , 2016, Oncotarget.

[22]  N. Suh,et al.  Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer , 2016, Oncotarget.

[23]  M. Soleimani,et al.  Tumor Associated Mesenchymal Stromal Cells Show Higher Immunosuppressive and Angiogenic Properties Compared to Adipose Derived MSCs. , 2015, Iranian journal of immunology : IJI.

[24]  Y. Eom,et al.  Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression , 2015, International journal of molecular sciences.

[25]  Ava Kwong,et al.  Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. , 2015, American journal of cancer research.

[26]  S. Baird,et al.  Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase‐1 and ‐2 , 2015, Molecular carcinogenesis.

[27]  H. Qiu,et al.  Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant , 2015, International journal of molecular medicine.

[28]  J. Yun,et al.  Human Umbilical Cord Blood Mesenchymal Stem Cell‐Derived PGE2 and TGF‐β1 Alleviate Atopic Dermatitis by Reducing Mast Cell Degranulation , 2015, Stem cells.

[29]  H. Huynh,et al.  Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  W. Woodward,et al.  Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model , 2015, Breast Cancer Research.

[31]  Qiang Z Yu,et al.  Apoptosis, autophagy, necroptosis, and cancer metastasis , 2015, Molecular Cancer.

[32]  N. Erin,et al.  Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists , 2015, Breast Cancer Research and Treatment.

[33]  A. Hollestelle,et al.  Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer. , 2015, Human pathology.

[34]  Yuan Cao,et al.  Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer , 2015, Disease Models & Mechanisms.

[35]  Bernard Klein,et al.  Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.

[36]  W. ElShamy,et al.  BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers , 2015, Breast Cancer Research.

[37]  F. Behbod,et al.  Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins , 2014, BMC Cancer.

[38]  W. ElShamy,et al.  BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin , 2014, Oncogene.

[39]  Shuwei Wang,et al.  The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). , 2014, International journal of oncology.

[40]  M. Kassem,et al.  Pleiotropic effects of cancer cells’ secreted factors on human stromal (mesenchymal) stem cells , 2013, Stem Cell Research & Therapy.

[41]  K. Anastassiadis,et al.  Differential Expression of Surface Markers in Mouse Bone Marrow Mesenchymal Stromal Cell Subpopulations with Distinct Lineage Commitment , 2012, PloS one.

[42]  R. Reis,et al.  Enhancement of osteogenic differentiation of human adipose derived stem cells by the controlled release of platelet lysates from hybrid scaffolds produced by supercritical fluid foaming. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[43]  G. Müller-Newen,et al.  Dynamics and non-canonical aspects of JAK/STAT signalling. , 2012, European journal of cell biology.

[44]  T. Maruyama,et al.  Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model , 2012, Laboratory Investigation.

[45]  Hong Li,et al.  Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells , 2012, Journal of Hematology & Oncology.

[46]  P. Miron,et al.  Abstract 5319: BRCA1-IRIS overexpression promotes formation of aggressive breast cancers , 2012 .

[47]  P. Miron,et al.  BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers , 2012, PloS one.

[48]  Yufang Shi,et al.  How mesenchymal stem cells interact with tissue immune responses. , 2012, Trends in immunology.

[49]  A. Inoue,et al.  Phospho‐Ser727 of STAT3 regulates STAT3 activity by enhancing dephosphorylation of phospho‐Tyr705 largely through TC45 , 2012, Genes to cells : devoted to molecular & cellular mechanisms.

[50]  A. Abdel‐Mageed,et al.  Prospective dual role of mesenchymal stem cells in breast tumor microenvironment , 2012, Breast Cancer Research and Treatment.

[51]  P. Dentelli,et al.  IL-3 is a novel target to interfere with tumor vasculature , 2011, Oncogene.

[52]  Wenming Li,et al.  PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP+-induced neuronal apoptosis , 2011, Neurochemistry International.

[53]  C. Lynch,et al.  Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. , 2011, Cancer letters.

[54]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[55]  G. Stark,et al.  Lysine methylation of promoter-bound transcription factors and relevance to cancer , 2011, Cell Research.

[56]  Hiroyuki Tomita,et al.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. , 2011, Cancer cell.

[57]  D. Banerjee,et al.  Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. , 2010, Experimental cell research.

[58]  G. Stark,et al.  Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.

[59]  T. Kishimoto.  IL-6: from its discovery to clinical applications. , 2010, International immunology.

[60]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[61]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[62]  A. Kavanaugh,et al.  Medical Management of Rheumatoid Arthritis , 2007 .

[63]  J. Mesirov,et al.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. , 2008, Cancer research.

[64]  C. Jorgensen,et al.  Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? , 2008, Stem cells.

[65]  Shahin Rafii,et al.  Migratory neighbors and distant invaders: tumor-associated niche cells. , 2008, Genes & development.

[66]  A. Spurdle,et al.  Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1 , 2008, Breast Cancer Research and Treatment.

[67]  D. Levy,et al.  IL-6 signaling via the STAT3/SOCS3 pathway: Functional Analysis of the Conserved STAT3 N-domain , 2006, Molecular and Cellular Biochemistry.

[68]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[69]  Dairong Wang,et al.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.

[70]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[71]  W. ElShamy,et al.  Identification of BRCA1-IRIS, a BRCA1 locus product , 2004, Nature Cell Biology.

[72]  J. Darnell,et al.  Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation , 2004, Molecular and Cellular Biology.

[73]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[74]  Mangi Mh,et al.  Interleukin-3 in hematology and oncology: current state of knowledge and future directions. , 1999 .

[75]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[76]  M. Mangi,et al.  Interleukin-3 in hematology and oncology: current state of knowledge and future directions. , 1999, Cytokines, cellular & molecular therapy.

[77]  S. Sapareto,et al.  Solid tumor preparation for flow cytometry using a standard murine model. , 1987, Cytometry.